Arimoclomol Safety Trial in ALS Complete

On July 24, the Los Angeles biopharmaceutical company CytRx (www.cytrx.com) announced it had completed its current dose determination and safety study in amyotrophic lateral sclerosis (ALS) of its drug arimoclomol, a small molecule that may improve cellular stress resistance.

The company plans to release results by the end of the year and, pending regulatory approval, begin a large-scale trial to test arimoclomol’s effectiveness.